Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Further considerations on model-independent bioavailability estimation

S Hwang, K C Kwan

    Journal of Pharmaceutical Sciences
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial).

    ESMO open·2025
    Same author

    A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma.

    ESMO open·2025
    Same author

    Mechanisms Tackling Salivary Gland Diseases with Extracellular Vesicle Therapies.

    Journal of dental research·2025
    Same author

    Non-standard employment and COVID-19 testing in South Korean workers.

    Public health·2023
    Same author

    Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry.

    Pulmonary pharmacology & therapeutics·2023
    Same author

    Risk factors for persistent pain after breast cancer surgery: a multicentre prospective cohort study.

    Anaesthesia·2023
    Same journal

    Green, renewable, or low-carbon? A framework for informed solvent selection in pharmaceutical sciences.

    Journal of pharmaceutical sciences·2026
    Same journal

    Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI.

    Journal of pharmaceutical sciences·2026
    Same journal

    Intranasal mucoadhesive chitosan microspheres of ranolazine: Formulation, design, and pharmacokinetic evaluation.

    Journal of pharmaceutical sciences·2026
    Same journal

    Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

    Journal of pharmaceutical sciences·2026
    Same journal

    A mathematical framework for predicting tablet weight variability from blend particle size distribution and tooling geometry.

    Journal of pharmaceutical sciences·2026
    Same journal

    Recrystallization can stop nitrosamine formation in ranitidine hydrochloride.

    Journal of pharmaceutical sciences·2026
    See all related articles

    This study revisits assumptions for model-independent bioavailability estimation, especially when no intravenous reference is available. A new procedure offers optimal relative bioavailability estimates by analyzing errors in non-intravenous scenarios.

    Area of Science:

    • Pharmacokinetics
    • Biopharmaceutics
    • Drug Development

    Background:

    • Model-independent bioavailability estimation is crucial for drug development.
    • Assumptions in these estimations, particularly with unavailable intravenous references, require scrutiny.
    • Nonrenal clearance constancy is a common, yet potentially limiting, assumption.

    Purpose of the Study:

    • To re-examine assumptions in model-independent bioavailability estimation.
    • To compare existing bioavailability estimators under specific challenging conditions.
    • To develop an improved method for estimating relative bioavailability.

    Main Methods:

    • Error analysis of bioavailability estimation procedures.
    • Comparison of different bioavailability estimators.

    Related Experiment Videos

  • Development of a novel estimation procedure based on error analysis.

    • Main Results:

    • Identified limitations in previous bioavailability estimation approximations.
    • Quantified errors associated with assuming constant nonrenal clearance.
    • Devised a procedure for optimal relative bioavailability estimation.

    Conclusions:

    • The developed procedure provides more accurate relative bioavailability estimates when intravenous references are absent.
    • This method enhances the reliability of bioavailability assessments in non-ideal clinical scenarios.
    • Optimized bioavailability estimation contributes to safer and more effective drug development.